MTOR and cancer: Growing evidence has suggested that the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, wherein MDR1 and NF-kappaB are downstream factors of this pathway, is closely related to the occurrence of drug resistance in cancer [21–23].